DTU Publications (2010-2019)

2014

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.

de Barros e Silva PGM. et al, (2014), Int J Cardiol, 176, 1126 - 1128

Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort: does the ADDITION validation add up?

Gray A. et al, (2014), Value Health, 17, 895 - 896

Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study

Preiss D. et al, (2014), Diabetes Obesity and Metabolism, 16, 1265 - 1268

Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored

McMurray JJV. et al, (2014), Lancet Diabetes and Endocrinology, 2, 843 - 851

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.

Holman RR. et al, (2014), Lancet, 384, 1097 - 1098

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.

Blood Pressure Lowering Treatment Trialists' Collaboration ., (2014), Lancet, 384, 591 - 598

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus

Holman RR., (2014), Nature Reviews Endocrinology, 10, 453 - 454

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

Holman RR. et al, (2016), International Journal of Endocrinology and Metabolism, 36

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

Holman RR. et al, (2014), Lancet, 383, 2008 - 2017

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR

Huffman KM. et al, (2014), Metabolism: Clinical and Experimental, 63, 554 - 561

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis

Yates T. et al, (2014), The Lancet, 383, 1059 - 1066

Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)

Davis TME. et al, (2014), Diabetic Medicine, 31, 200 - 207

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial

Preiss D. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 116 - 124

2013

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

Green JB. et al, (2013), American Heart Journal, 166

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Latini R. et al, (2013), Am Heart J, 166, 935 - 40.e1

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Preiss D. et al, (2013), Stroke, 44, 2590 - 2593

UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

Hayes AJ. et al, (2013), Diabetologia, 56, 1925 - 1933

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.

Bethel MA. et al, (2013), Am J Cardiol, 112, 231 - 237

Evaluation of a self-administered oral glucose tolerance test.

Bethel MA. et al, (2013), Diabetes Care, 36, 1483 - 1488

Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.

Leal J. et al, (2013), Diabetes Care, 36, 1541 - 1546

Metformin and mortality. Reply to Lund SS [letter].

Stevens RJ. et al, (2013), Diabetologia, 56, 939 - 940

Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.

Davis TME. et al, (2013), Circulation, 127, 980 - 987

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive

Holman RR., (2013), Nature Reviews Endocrinology, 9, 67 - 68

2012

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.

Preiss D. et al, (2012), BMJ Open, 2

Prediabetes and the risk of diabetes.

McMurray JJV. et al, (2012), Lancet, 380, 1225 - 1226

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Stevens RJ. et al, (2012), Diabetologia, 55, 2593 - 2603

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study

Mcmurray JJV. et al, (2012), Journal of Clinical Hypertension, 14, 731 - 731

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

van Leeuwen N. et al, (2012), Diabetologia, 1 - 7

Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice

Price HC. et al, (2012), Practical Diabetes, 29, 61 - 64

Understanding the outcomes of multi-centre clinical trials: A qualitative study of health professional experiences and views

Lawton J. et al, (2012), Social Science and Medicine, 74, 574 - 581

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

Punthakee Z. et al, (2012), Diabetologia, 55, 36 - 45

2011

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.

Farmer AJ. et al, (2011), Diabetes Obes Metab, 13, 1136 - 1141

Incidence of diabetes following ramipril or rosiglitazone withdrawal

Holman RR. et al, (2011), Diabetes Care, 34, 1265 - 1269

Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial.

Lawton J. et al, (2011), Trials, 12

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Lachin JM. et al, (2011), Clin J Am Soc Nephrol, 6, 1032 - 1040

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

Kahn SE. et al, (2011), Diabetes, 60, 1552 - 1560

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.

ARB Trialists Collaboration ., (2011), J Hypertens, 29, 623 - 635

2010

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.

GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group . et al, (2011), Nat Genet, 43, 117 - 120

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial

Neil HAW. et al, (2010), Atherosclerosis, 213, 512 - 517

Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences.

Jenkins N. et al, (2010), Diabetes Care, 33, 2178 - 2180

Recommendations for biomarker identification and qualification in clinical proteomics.

Mischak H. et al, (2010), Sci Transl Med, 2

Life expectancy in individuals with type 2 diabetes: implications for annuities.

Price HC. et al, (2010), Med Decis Making, 30, 409 - 414

Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Reply to Wägner AM, Mauricio D [letter].

Farmer AJ. et al, (2010), Diabetologia

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.

Krum H. et al, (2010), Cardiovasc Ther, 28, 124 - 132

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group . et al, (2010), N Engl J Med, 362, 1463 - 1476

Effect of valsartan on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group . et al, (2010), N Engl J Med, 362, 1477 - 1490

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.

Kahn R. et al, (2010), Lancet, 375, 1365 - 1374

Insulin Regimens in Type 2 Diabetes REPLY

Holman RR. and Darbyshire JL., (2010), NEW ENGLAND JOURNAL OF MEDICINE, 362, 960 - 960

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.

Pal A. et al, (2010), Diabetes Care, 33, 252 - 257

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Kahn SE. et al, (2010), Diabetes Care, 33, 177 - 183

PAST PUBLICATIONS

Cookies on this website